Dr. Armin Rehm
A prerequisite to develop new approaches for the treatment of malignant lymphomas is a thorough understanding of the molecular mechanisms that govern oncogenic transformation. Our group is interested in the role of transcription factor networks and signaling pathways with a special emphasis on cellular dedifferentiation and reprogramming of lymphoid malignancies. To this end, we investigate the link between alterations in physiological transcription factor activities, lineage-inappropriate gene expression and oncogenic transformation. In this context, we focus in particular on the transcription factor E2A, which is essential for the development of B and T lymphoid cells. Its function is in various lymphoma entities disrupted by genomic alterations as well as functional antagonism. In addition, it is the aim of the group to translate these findings into new treatment strategies for human B and T cellderived malignancies.